Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a week off GLP-1 drugs make endoscopies safer and more effective?

NCT ID NCT07736911

Disease control Sponsor: Fu Jen Catholic University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This trial asks whether pausing GLP-1 receptor agonists (like semaglutide or tirzepatide) for one week before an upper endoscopy leads to a cleaner stomach and fewer repeat procedures. About 140 adults who take these drugs and are scheduled for an endoscopy will be randomly assigned to either stop their medication for a week or continue as usual. The goal is to see if a simple drug holiday can improve the quality of the exam and reduce the need for a second scope.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stopping GLP-1 receptor agonists (like semaglutide or tirzepatide) for one week before an upper endoscopy
What this could lead to
If a one-week pause improves stomach visibility, it could lead to a simple, safer pre-endoscopy guideline for people on these popular diabetes and weight-loss drugs.
What could go wrong
This is a small, single-center trial, so results may not apply broadly. Stopping GLP-1 drugs could cause blood sugar spikes or other side effects in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week). * Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose. * Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication. * Age between 18 and 70 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Provision of written informed consent. * Outpatient status. * If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD. Exclusion Criteria: * • Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis). * History of prior upper gastrointestinal resection (stomach, intestine, or esophagus). * Any other condition deemed inappropriate by the treating physician. * Body mass index (BMI) \> 40 kg/m². * Liver cirrhosis. * Parkinson's disease. * Dementia. * Use of tricyclic antidepressants or opioid medications for more than 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLP-1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLP-1

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • FJUH

    RECRUITING

    New Taipei City, Taiwan, 24352, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.